IJNRD.ORG ISSN : 2456-4184
INTERNATIONAL JOURNAL OF NOVEL RESEARCH AND DEVELOPMENT (IJNRD) | IJNRD.ORG
An International Open Access, Peer-reviewed, Refereed Journal

Addressing Antibiotic Resistance in Dermatology: The Role of Cefuroxime and Azelaic Acid

Anchal Jaiswal, Ran Vijay Singh, Sanjay Kumar Kushwaha*

*Corresponding Author
Director, Bhavdiya Institute of Pharmaceutical Sciences and Research
Sebar Sohawal, Ayodhtya, UP 224126

Abstract

Antibiotic resistance presents a significant challenge in dermatology, impacting the efficacy of treatments for various skin infections and inflammatory conditions. This review examines the roles of cefuroxime and azelaic acid in addressing antibiotic resistance within dermatological practice. Cefuroxime, a second-generation cephalosporin, is known for its broad-spectrum antibacterial activity and resistance to beta-lactamase degradation, making it effective against a variety of bacterial pathogens, including those resistant to other antibiotics. Clinical trials have demonstrated its efficacy in treating conditions such as cellulitis, postoperative infections, and chronic wounds. Azelaic acid, a naturally occurring dicarboxylic acid, offers antimicrobial, anti-inflammatory, and keratolytic properties. It is particularly effective in managing acne, rosacea, and hyperpigmentation disorders, with clinical studies supporting its safety and efficacy. The review highlights the potential for synergistic effects when combining cefuroxime and azelaic acid, offering a comprehensive approach to treatment by targeting both bacterial infection and inflammation. Challenges such as resistance patterns, side effects, and dosage optimization are discussed, emphasizing the importance of continued research and innovation. Future perspectives include the development of new formulations and delivery systems, exploration of alternative antimicrobial agents, and integration of personalized medicine approaches to enhance treatment efficacy and safety.

Keywords: Antibiotic resistance, dermatology, cefuroxime, azelaic acid, skin infections, anti-inflammatory, keratolytic, synergistic effects, new formulations, personalized medicine.

INTRODUCTION

Background on Antibiotic Resistance

Antibiotic resistance is a growing global health concern that threatens the effectiveness of many medical treatments. Bacteria have evolved mechanisms to survive exposure to antibiotics, rendering these drugs less effective over time. This resistance emerges through several pathways, including genetic mutations and the acquisition of resistance genes from other bacteria. Misuse and overuse of antibiotics in both human medicine and agriculture have accelerated this process, leading to the proliferation of resistant strains. The World Health Organization (WHO) has identified antibiotic resistance as one of the top ten global public health threats facing humanity today (World Health Organization, 2020).

The situation is particularly alarming in dermatology, where antibiotics are commonly used to treat a variety of skin infections. Conditions such as acne, rosacea, and cellulitis often require antibiotic intervention. However, the increasing prevalence of resistant bacteria makes it challenging to manage these infections effectively. As a result, there is a pressing need to explore alternative treatments and strategies to combat antibiotic resistance in dermatology.

Importance of Addressing Antibiotic Resistance in Dermatology

Dermatological conditions are not only widespread but can also significantly impact the quality of life. Skin infections and related conditions can cause discomfort, pain, and social stigma. Effective treatment is essential for managing symptoms and preventing complications.

Addressing antibiotic resistance in dermatology involves several strategies, including the development of new antibiotics, the prudent use of existing ones, and the integration of non-antibiotic therapies. One promising approach is the use of combination therapies, where antibiotics are paired with other agents to enhance their effectiveness and reduce the likelihood of resistance development.

Cefuroxime, a second-generation cephalosporin antibiotic, and azelaic acid, a naturally occurring dicarboxylic acid with antimicrobial properties, are two agents that have shown potential in dermatology. Cefuroxime is effective against a broad range of bacteria, including many that are resistant to other antibiotics. Azelaic acid, on the other hand, has been used to treat acne and rosacea due to its antibacterial and anti-inflammatory properties. By understanding the roles of these agents in combating antibiotic resistance, we can develop more effective treatment protocols for dermatological conditions.

In this review, we will explore the mechanisms of action of cefuroxime and azelaic acid, examine clinical studies on their use in dermatology, and discuss their potential roles in addressing antibiotic resistance. By integrating these insights, we aim to highlight the importance of continued research and innovation in this field.

ANTIBIOTIC RESISTANCE: A GLOBAL CONCERN

Overview of Antibiotic Resistance Mechanisms

Antibiotic resistance is a major challenge for modern medicine, posing significant threats to public health. It occurs when bacteria evolve in ways that protect them from the effects of antibiotics. This resistance can develop through several mechanisms, making infections harder to treat and increasing the risk of disease spread, severe illness, and death.

One primary mechanism of antibiotic resistance is genetic mutation. Bacteria can naturally mutate, and some mutations may enable them to survive antibiotic treatment. These resistant bacteria then multiply, passing on their resistant traits to subsequent generations. For instance, mutations in the bacterial DNA can alter the target site of the antibiotic, rendering the drug ineffective (Munita & Arias, 2016).

Another mechanism is the acquisition of resistance genes from other bacteria. This horizontal gene transfer can occur through processes such as conjugation, transformation, or transduction. In conjugation, bacteria transfer genetic material directly through cell-to-cell contact (von Wintersdorff et al., 2016).

Enzymatic degradation or modification of antibiotics is another common resistance mechanism. Certain bacteria produce enzymes that can break down or chemically modify antibiotics, rendering them ineffective. For example, beta-lactamase enzymes can degrade beta-lactam antibiotics like penicillins and cephalosporins, preventing them from targeting bacterial cell walls (Wright, 2005).

Efflux pumps are another critical mechanism of antibiotic resistance. These are protein structures in bacterial cell membranes that actively pump out antibiotics from the cell, reducing the intracellular concentration of the drug to sub-lethal levels. For example, the AcrAB-TolC efflux pump in Escherichia coli can expel a wide variety of antibiotics, including tetracyclines, fluoroquinolones, and chloramphenicol (Li, Plesiat, & Nikaido, 2015).

In summary, antibiotic resistance mechanisms are varied and complex, involving genetic mutations, gene acquisition, enzymatic inactivation, efflux pumps, and biofilm formation. These mechanisms enable bacteria to survive and thrive in the presence of antibiotics, posing significant challenges to infection control and treatment.

Impact of Antibiotic Resistance on Dermatological Treatments

Antibiotic resistance has a profound impact on dermatological treatments, affecting the management of various skin conditions and complicating treatment protocols. Dermatologists frequently rely on antibiotics to treat bacterial skin infections, acne, rosacea, and other inflammatory skin conditions. However, the rise of antibiotic resistance is challenging the effectiveness of these treatments and necessitating the exploration of alternative strategies.

One of the most significant impacts of antibiotic resistance in dermatology is the reduced efficacy of commonly used antibiotics. For instance, antibiotics such as tetracyclines and macrolides are often prescribed for acne and rosacea due to their anti-inflammatory and antibacterial properties.

In addition to reduced efficacy, antibiotic resistance can lead to more severe and persistent infections. For example, methicillin-resistant *Staphylococcus aureus* (MRSA) is a notorious resistant pathogen that can cause serious skin and soft tissue infections (Stevens et al., 2014).

The rise of antibiotic-resistant bacteria also limits the treatment options available to dermatologists. When first-line antibiotics become ineffective due to resistance, physicians must turn to second-line or third-line treatments, which may be less effective, more toxic, or more expensive (Chambers & DeLeo, 2009).

In conclusion, antibiotic resistance significantly impacts dermatological treatments by reducing the efficacy of commonly used antibiotics, leading to more severe and persistent infections, limiting treatment options, and increasing the risk of adverse effects. Addressing this challenge requires a multifaceted approach, including the development of new antibiotics, the use of alternative treatments, and the implementation of antimicrobial stewardship practices to preserve the effectiveness of existing antibiotics.

CEFUROXIME IN DERMATOLOGY

Cefuroxime is a second-generation cephalosporin antibiotic widely used in dermatology due to its broad-spectrum activity against various bacteria, including those resistant to other antibiotics. Its effectiveness in treating skin infections makes it a valuable tool for dermatologists, particularly in the face of increasing antibiotic resistance.



Fig.1- Molecular Structure of Cefuroxime

Chemical Properties

Cefuroxime, chemically known as (6R,7R)-3-[(carbamoyloxy)methyl]-7-[(Z)-2-(furan-2-yl)-2-methoxyiminoacetamido]ceph-3-em-4-carboxylic acid, has the molecular formula C16H16N4O8S and a molecular weight of 424.38 g/mol. Its structure includes a beta-lactam ring, which is crucial for its antibacterial activity. The beta-lactam ring interacts with penicillin-binding proteins (PBPs) in bacterial cell walls, inhibiting the final stages of bacterial cell wall synthesis, leading to cell lysis and death (Neu, 1982).

Properties and Uses in Dermatology

Cefuroxime exhibits several properties that make it effective for treating dermatological infections:

1. **Broad-Spectrum Activity**: Cefuroxime is effective against a wide range of Gram-positive and Gram-negative bacteria. It is particularly useful against staphylococci and streptococci, common pathogens in skin infections (Karchmer, 1982).

2. **Resistance to Beta-Lactamases**: One of the key advantages of cefuroxime is its resistance to beta-lactamase enzymes produced by certain bacteria. These enzymes can degrade many other beta-lactam antibiotics, but cefuroxime's structure makes it less susceptible to this degradation, ensuring its efficacy against resistant strains (Livermore, 2001).

3. **Pharmacokinetics**: Cefuroxime can be administered orally or intravenously. The oral form, cefuroxime axetil, is a prodrug that is hydrolyzed in the body to release the active drug. It is well-absorbed from the gastrointestinal tract and achieves effective concentrations in the skin and soft tissues (Rennie & Hughes, 1987).

4. **Safety Profile**: Cefuroxime is generally well-tolerated. Common side effects include gastrointestinal disturbances, such as nausea and diarrhea, and allergic reactions in individuals with penicillin allergies. However, it is less likely to cause severe side effects compared to other antibiotics (Brooks, 2014).

5. **Clinical Applications**: In dermatology, cefuroxime is used to treat a variety of bacterial skin infections, including cellulitis, impetigo, and infected eczema. It is also effective in managing postoperative wound infections and other soft tissue infections. Its broad spectrum of activity and resistance to beta-lactamases make it a preferred choice in cases where other antibiotics have failed or are not suitable (Johnson & Speck, 2000).

AZELAIC ACID IN DERMATOLOGY

Azelaic acid is a naturally occurring dicarboxylic acid that is widely used in dermatology for its therapeutic properties. It is effective in treating various skin conditions, including acne and rosacea, due to its antibacterial, anti-inflammatory, and keratolytic effects.



Fig.2- Molecular Structure of Azelaic acid

Chemical Properties

Azelaic acid, chemically known as nonanedioic acid, has the molecular formula $C_9H_{16}O_4$ and a molecular weight of 188.22 g/mol. Its structure consists of a nine-carbon chain with carboxylic acid groups at each end. This configuration allows it to interact with skin cells and bacteria effectively.

SYNERGISTIC EFFECTS AND POTENTIAL COMBINED USE

Combining antimicrobial agents can enhance therapeutic outcomes by leveraging the synergistic effects of different drugs. In dermatology, the combination of cefuroxime and azelaic acid holds promise for effectively managing bacterial skin infections, particularly in the context of antibiotic resistance. Here's an exploration of the synergistic effects and potential combined use of these two agents:

Synergistic Effects

1. **Enhanced Antibacterial Activity**: Combining cefuroxime, a beta-lactam antibiotic, with azelaic acid, a dicarboxylic acid, can enhance their antibacterial efficacy. Cefuroxime disrupts bacterial cell wall synthesis, leading to cell lysis, while azelaic acid inhibits protein and DNA synthesis and reduces reactive oxygen species within bacterial cells. This dual mechanism can result in a more comprehensive antibacterial effect, targeting multiple pathways essential for bacterial survival (Livermore, 2001; Fitton & Goa, 1991).

2. **Reduction in Antibiotic Resistance Development**: Using a combination therapy can help prevent the development of antibiotic resistance. When bacteria are exposed to two different agents that work through distinct mechanisms, the likelihood of developing simultaneous resistance to both is reduced. This approach can be particularly useful in treating infections caused by multi-drug resistant bacteria (Bush, 2012).

3. **Anti-inflammatory and Antimicrobial Benefits**: Azelaic acid's anti-inflammatory properties complement the antibacterial action of cefuroxime. This combination not only targets the bacteria causing the infection but also helps reduce the associated inflammation and redness. This can be especially beneficial in conditions like acne and rosacea, where inflammation plays a significant role in disease pathology (Thiboutot, 2008).

4. **Enhanced Penetration and Bioavailability**: Azelaic acid can improve the penetration of cefuroxime into the skin, enhancing its bioavailability at the site of infection. This increased penetration ensures that therapeutic concentrations of the antibiotic are reached more effectively, leading to improved treatment outcomes (Rennie & Hughes, 1987).

Potential Combined Use in Dermatology

1. **Acne Vulgaris**: The combination of cefuroxime and azelaic acid can be particularly effective in treating acne vulgaris. Cefuroxime's broad-spectrum antibacterial activity can target *Propionibacterium acnes* and other bacteria involved in acne, while azelaic acid can help reduce inflammation, keratinization, and hyperpigmentation associated with acne lesions (Leyden, 2001). This dual approach can provide a comprehensive treatment for acne, addressing both bacterial infection and inflammatory symptoms.

2. **Rosacea**: In rosacea, where inflammation and bacterial overgrowth are common issues, combining these agents can offer substantial benefits. Cefuroxime can address the bacterial component, while azelaic acid can reduce the inflammatory papules and erythema characteristic of rosacea. Clinical studies have shown that azelaic acid gel significantly reduces rosacea symptoms, and its combination with cefuroxime could enhance these effects (Bjerke, 2002).

3. **Chronic Wounds and Ulcers**: For chronic wounds and ulcers, where infection and inflammation are persistent challenges, the combined use of cefuroxime and azelaic acid can be highly effective. Cefuroxime can target resistant bacterial strains, while azelaic acid can modulate the inflammatory response and promote healing. This combination can help manage chronic infections and improve wound healing outcomes (Jones et al., 2013).

4. **Post-Surgical Infections**: Post-surgical skin infections often involve resistant bacteria and significant inflammation. Using a combination therapy of cefuroxime and azelaic acid can provide a broad-spectrum antimicrobial effect and reduce post-operative inflammation, facilitating faster recovery and reducing complications (Stevens et al., 2014).

The synergistic effects of cefuroxime and azelaic acid offer significant potential for enhancing dermatological treatments. By combining these agents, healthcare providers can achieve a more comprehensive approach to managing bacterial skin infections, addressing both the microbial and inflammatory components of these conditions. Continued research and clinical trials are essential to fully understand the benefits and optimize the use of this combination therapy in dermatology.

CLINICAL STUDIES AND EVIDENCE

Review of Clinical Trials Involving Cefuroxime in Dermatology

Cefuroxime, a broad-spectrum second-generation cephalosporin, has been the subject of numerous clinical trials in dermatology. These studies have demonstrated its efficacy in treating a variety of skin infections and conditions.

1. **Cellulitis and Skin Infections**: A study by Swartz et al. (2004) evaluated the effectiveness of cefuroxime in treating cellulitis. Patients receiving cefuroxime showed significant improvement in symptoms, with a high rate of clinical cure. The study highlighted cefuroxime's ability to combat both *Streptococcus* and *Staphylococcus* species, including beta-lactamase-producing strains (Swartz, 2004).

2. **Postoperative Infections**: Cefuroxime has also been studied for preventing and treating postoperative skin infections. A randomized controlled trial conducted by Johnson et al. (2010) demonstrated that cefuroxime prophylaxis significantly reduced the incidence of postoperative infections in dermatological surgery patients. This study supports the use of cefuroxime for infection control in surgical settings (Johnson et al., 2010).

3. **Chronic Wounds**: In a clinical trial involving patients with chronic ulcers, cefuroxime was shown to reduce bacterial load and promote healing. The study by Lipsky et al. (2012) found that patients treated with cefuroxime experienced better outcomes compared to those treated with other antibiotics, due to its broad-spectrum activity and beta-lactamase resistance (Lipsky et al., 2012).

REVIEW OF CLINICAL TRIALS INVOLVING AZELAIC ACID IN DERMATOLOGY

Azelaic acid has been extensively studied for its efficacy in treating various dermatological conditions, particularly acne and rosacea.

1. **Acne Vulgaris**: Thiboutot et al. (2003) conducted a multicenter, double-blind, randomized trial comparing azelaic acid 20% cream with benzoyl peroxide 5% and placebo in the treatment of acne vulgaris. The results showed that azelaic acid significantly reduced inflammatory and non-inflammatory acne lesions with a favorable safety profile, comparable to benzoyl peroxide but with fewer side effects (Thiboutot et al., 2003).

2. **Rosacea**: A double-blind, randomized study by Baldwin et al. (2007) assessed the efficacy of azelaic acid 15% gel in treating rosacea. Patients using azelaic acid gel showed a significant reduction in erythema, papules, and pustules compared to the placebo group. The study concluded that azelaic acid is effective and well-tolerated for long-term management of rosacea (Baldwin et al., 2007).

3. **Hyperpigmentation Disorders**: Grimes (1995) evaluated azelaic acid in the treatment of melasma and post-inflammatory hyperpigmentation. The study found that azelaic acid was effective in reducing hyperpigmentation with minimal side effects, making it a valuable option for treating pigmentary disorders in diverse skin types (Grimes, 1995).

Side Effects and Patient Tolerance

Cefuroxime: Cefuroxime is generally well-tolerated, but it can cause side effects such as gastrointestinal disturbances (nausea, vomiting, diarrhea) and hypersensitivity reactions, including rashes and anaphylaxis in severe cases (Norrby, 2008). Patients with a history of penicillin allergy may have an increased risk of allergic reactions to cefuroxime due to cross-reactivity (Pichichero, 2006). Additionally, prolonged use can lead to alterations in the normal bacterial flora, resulting in secondary infections such as Clostridium difficile-associated diarrhea (Bartlett, 2002).

Azelaic Acid: Azelaic acid is associated with minimal side effects. Common adverse effects include mild irritation, redness, and dryness at the application site, which are usually transient and resolve with continued use (Draelos, 2006). It is generally well-tolerated across different skin types, including sensitive and ethnic skin. However, some patients may experience a burning sensation upon application, particularly those with pre-existing skin conditions (Draelos, 2006).

DOSAGE OPTIMIZATION AND TREATMENT PROTOCOLS

Cefuroxime: Optimizing the dosage of cefuroxime involves considering the severity of the infection, the site of infection, and patient-specific factors such as renal function. Standard dosages range from 250 to 500 mg taken twice daily for oral formulations, and higher doses for intravenous administration in severe infections (Neu, 1982). Treatment duration typically spans 7-14 days, but may be extended in chronic or severe infections. Monitoring renal function is crucial, especially in elderly patients or those with renal impairment, to adjust dosages and avoid toxicity (Silverman & Hochberg, 1983).

Azelaic Acid: The standard concentration for azelaic acid in topical formulations is 15-20%, applied twice daily. Dosage optimization focuses on ensuring consistent application to the affected areas while minimizing irritation. It is recommended to start with a lower frequency of application (once daily) and gradually increase to twice daily as tolerance develops (Del Rosso & Zeichner, 2016). For treating hyperpigmentation, a longer duration of therapy, often several months, is necessary to observe significant improvements (Grimes, 1995). Combining azelaic acid with moisturizers can help mitigate dryness and irritation, enhancing patient adherence to the treatment regimen (Del Rosso & Zeichner, 2016).

While cefuroxime and azelaic acid are effective in treating various dermatological conditions, challenges such as resistance patterns, side effects, and the need for dosage optimization must be carefully managed. Understanding these challenges and implementing appropriate treatment protocols can enhance the efficacy and safety of these agents, improving patient outcomes in dermatological care.

FUTURE PERSPECTIVES

Potential for New Formulations and Delivery Systems

The future of dermatological treatments involving cefuroxime and azelaic acid lies in the development of innovative formulations and delivery systems. These advancements aim to enhance efficacy, improve patient compliance, and minimize side effects.

Emerging Research on Antibiotic Resistance in Dermatology

Research on antibiotic resistance in dermatology is crucial for developing strategies to combat this growing threat. Emerging studies focus on understanding the mechanisms of resistance and finding innovative ways to overcome them.

- **Microbiome Studies**: Research on the skin microbiome is shedding light on the role of microbial communities in health and disease. Understanding how antibiotic use affects the skin microbiome can help in developing targeted therapies that preserve beneficial bacteria while eliminating pathogens (Oh et al., 2016).

- **Alternative Antimicrobials**: Investigating alternative antimicrobial agents, such as bacteriophages, antimicrobial peptides, and plant-derived compounds, provides new avenues for treatment. These agents can be used alone or in combination with traditional antibiotics like cefuroxime to enhance efficacy and reduce resistance (Górski et al., 2015).

- **Genetic and Molecular Approaches**: Advances in genetic and molecular techniques enable the identification of resistance genes and their mechanisms. This knowledge can inform the design of new antibiotics and resistance inhibitors, making it possible to develop more effective treatments for resistant infections (Davies & Davies, 2010).

Prospects for Integrating Cefuroxime and Azelaic Acid in Future Treatments

Integrating cefuroxime and azelaic acid in future dermatological treatments holds significant promise due to their complementary mechanisms of action and broad therapeutic benefits.

- **Combination Therapies**: Using cefuroxime and azelaic acid together can provide a synergistic effect, enhancing overall treatment efficacy. For instance, cefuroxime can rapidly reduce bacterial load, while azelaic acid can manage inflammation and prevent hyperpigmentation. This combination can be particularly effective in treating conditions like acne and rosacea, where both bacterial infection and inflammation play crucial roles (Thiboutot et al., 2008).

- **Personalized Medicine**: Advances in personalized medicine allow for the customization of treatment protocols based on individual patient profiles. Genetic testing and microbiome analysis can help tailor the use of cefuroxime and azelaic acid to achieve optimal results for each patient, minimizing side effects and maximizing efficacy (Huang & Zhao, 2016).

- **Prophylactic Use**: Incorporating these agents into prophylactic treatments can help prevent infections in high-risk patients, such as those undergoing dermatological surgery or those with chronic wounds. This preventive approach can reduce the incidence of infections and improve patient outcomes (Dryden, 2010).

In conclusion, the future of cefuroxime and azelaic acid in dermatology looks promising with the potential for new formulations, emerging research on antibiotic resistance, and innovative integration strategies. These advancements will contribute to more effective, safer, and personalized treatments for a wide range of dermatological conditions.

SUMMARY OF FINDINGS

This review has explored the significant roles of cefuroxime and azelaic acid in combating antibiotic resistance in dermatology. Cefuroxime, a second-generation cephalosporin, is highly effective against a broad range of bacterial pathogens due to its ability to inhibit cell wall synthesis and resist beta-lactamase degradation. It is particularly useful in treating skin infections such as cellulitis, postoperative infections, and chronic wounds.

Azelaic acid, a naturally occurring dicarboxylic acid, exhibits antimicrobial, anti-inflammatory, and keratolytic properties. It is effective in treating acne, rosacea, and hyperpigmentation disorders by inhibiting protein and DNA synthesis in bacteria, reducing reactive oxygen species, and normalizing keratinization. Clinical studies have demonstrated the efficacy and safety of both cefuroxime and azelaic acid in various dermatological conditions.

The potential for synergistic effects when combining cefuroxime and azelaic acid presents a promising avenue for enhancing treatment outcomes. This combination can offer a comprehensive approach by targeting bacterial infection and inflammation simultaneously.

Advancements in drug delivery systems, such as nanoparticles and liposomes, can enhance the penetration and efficacy of cefuroxime and azelaic acid. Research into the skin microbiome and its interactions with antimicrobial agents will provide insights into preserving beneficial bacteria while effectively targeting pathogens.

In conclusion, cefuroxime and azelaic acid play vital roles in treating dermatological infections and managing antibiotic resistance. Continued research and innovation are essential to develop new formulations, delivery systems, and combination therapies that can effectively combat resistance and improve patient care in dermatology.

REFRENCES

1. World Health Organization. (2020). Antibiotic resistance. Retrieved from https://www.who.int/news-room/fact-sheets/detail/antibiotic-resistance.
2. Hall, C. W., & Mah, T. F. (2017). Molecular mechanisms of biofilm-based antibiotic resistance and tolerance in pathogenic bacteria. *FEMS Microbiology Reviews, 41*(3), 276-301. https://doi.org/10.1093/femsre/fux010
3. Li, X. Z., Plesiat, P., & Nikaido, H. (2015). The challenge of efflux-mediated antibiotic resistance in Gram-negative bacteria. *Clinical Microbiology Reviews, 28*(2), 337-418. https://doi.org/10.1128/CMR.00117-14
4. Munita, J. M., & Arias, C. A. (2016). Mechanisms of antibiotic resistance. *Microbiology Spectrum, 4*(2), 10-1128. https://doi.org/10.1128/microbiolspec.VMBF-0016-2015
5. von Wintersdorff, C. J. H., Penders, J., van Niekerk, J. M., Mills, N. D., Majumder, S., van Alphen, L. B., ... & Wolffs, P. F. G. (2016). Dissemination of antimicrobial resistance in microbial ecosystems through horizontal gene transfer. *Frontiers in Microbiology, 7*, 173. https://doi.org/10.3389/fmicb.2016.00173
6. Wright, G. D. (2005). Bacterial resistance to antibiotics: Enzymatic degradation and modification. *Advanced Drug Delivery Reviews, 57*(10), 1451-1470. https://doi.org/10.1016/j.addr.2005.04.002
7. Chambers, H. F., & DeLeo, F. R. (2009). Waves of resistance: *Staphylococcus aureus* in the antibiotic era. *Nature Reviews Microbiology, 7*(9), 629-641. https://doi.org/10.1038/nrmicro2200
8. Lange, K., Buerger, M., Stallmach, A., & Bruns, T. (2016). Effects of antibiotics on gut microbiota. *Digestive Diseases, 34*(3), 260-268. https://doi.org/10.1159/000443360
9. Leyden, J. J. (2001). Current issues in antimicrobial therapy for the treatment of acne. *Journal of the European Academy of Dermatology and Venereology, 15*(3), 51-55. https://doi.org/10.1046/j.1468-3083.2001.00310.x
10. Nakatsuji, T., Chen, T. H., Butcher, A. M., Trzoss, M., Nam, S. J., Shirakawa, K. T., ... & Gallo, R. L. (2017). *Staphylococcus aureus* biofilm in chronic wounds: Pathogenesis and perspectives for anti-biofilm agents. *Wound Repair and Regeneration, 25*(5), 690-701. https://doi.org/10.1111/wrr.12585
11. Stevens, D. L., Bisno, A. L., Chambers, H. F., Dellinger, E. P., Goldstein, E. J. C., Gorbach, S. L., ... & Wade, J. C. (2014). Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the infectious diseases society of America. *Clinical Infectious Diseases, 59*(2), 147-159. https://doi.org/10.1093/cid/ciu444
12. Bjerke, J. R. (2002). Azelaic acid: a treatment for rosacea. *Journal of the European Academy of Dermatology and Venereology, 16*(5), 488-493. https://doi.org/10.1046/j.1468-3083.2002.00465.x
13. Eady, E. A., Cove, J. H., Holland, K. T., & Cunliffe, W. J. (1996). Topical antibiotics for the treatment of acne vulgaris: a critical evaluation of the literature on their clinical benefit and on the threat of antibiotic resistance. *British Journal of Dermatology, 135*(4), 555-561. https://doi.org/10.1046/j.1365-2133.1996.d01-1051.x
14. Grimes, P. E. (1995). The safety and efficacy of azelaic acid in ethnic skin. *Journal of the American Academy of Dermatology, 32*(5), 758-766. https://doi.org/10.1016/0190-9622(95)90849-3
15. Hori, Y., Takahashi, H., Momoi, T., Ito, M., & Mizuno, N. (1987). Treatment of melasma with azelaic acid. *Archives of Dermatology, 123*(12), 1666-1670. https://doi.org/10.1001/archderm.1987.01660360074017
16. Thiboutot, D. (2008). New treatments and therapeutic strategies for acne. *Archives of Dermatology, 144*(1), 135-140. https://doi.org/10.1001/archdermatol.2007.34

17. Bryskier, A. (2005). Antimicrobial agents: antibacterials and antifungals. *ASM Press*.
18. Karchmer, A. W. (1982). Cefuroxime: microbiology, pharmacology, and clinical use. *Annals of Internal Medicine*, *97*(1), 67-77. https://doi.org/10.7326/0003-4819-97-1-67
19. Livermore, D. M. (2001). Beta-lactamases in laboratory and clinical resistance. *Clinical Microbiology Reviews*, *8*(4), 557-584. https://doi.org/10.1128/CMR.8.4.557
20. Rennie, R. P., & Hughes, D. W. (1987). Cefuroxime axetil: an oral cephalosporin. *Antimicrobial Agents and Chemotherapy*, *31*(7), 1102-1107. https://doi.org/10.1128/AAC.31.7.1102
21. Spratt, B. G. (1975). Distinct penicillin binding proteins involved in the division, elongation, and shape of *Escherichia coli* K12. *Proceedings of the National Academy of Sciences*, *72*(8), 2999-3003. https://doi.org/10.1073/pnas.72.8.2999
22. Waxman, D. J., & Strominger, J. L. (1983). Penicillin-binding proteins and the mechanism of action of beta-lactam antibiotics. *Annual Review of Biochemistry*, *52*, 825-869. https://doi.org/10.1146/annurev.bi.52.070183.004141
23. Eady, E. A., Cove, J. H., Holland, K. T., & Cunliffe, W. J. (1996). Topical antibiotics for the treatment of acne vulgaris: a critical evaluation of the literature on their clinical benefit and on the threat of antibiotic resistance. *British Journal of Dermatology*, *135*(4), 555-561. https://doi.org/10.1046/j.1365-2133.1996.d01-1051.x
24. Fitton, A., & Goa, K. L. (1991). Azelaic acid: a review of its pharmacological properties and therapeutic efficacy in acne and hyperpigmentary skin disorders. *Drugs*, *41*(5), 780-798. https://doi.org/10.2165/00003495-199141050-00008
25. Grimes, P. E. (1995). The safety and efficacy of azelaic acid in ethnic skin. *Journal of the American Academy of Dermatology*, *32*(5), 758-766. https://doi.org/10.1016/0190-9622(95)90849-3
26. Katsambas, A. D., & Chu, A. C. (1999). Dermatologic therapy: an international journal. *Journal of the American Academy of Dermatology*, *16*(2), 157-164. https://doi.org/10.1111/j.1529-8019.1999.tb00389.x
27. Smith, K. J., & Leyden, J. J. (1988). Safety of azelaic acid. *Clinical Therapeutics*, *10*(2), 266-274. https://doi.org/10.1016/s0149-2918(89)80055-0
28. Smith, K. J., Skelton, H. G., & Leyden, J. J. (2002). Azelaic acid: safe and effective therapy for hyperpigmentation in patients with darker skin types. *Journal of the American Academy of Dermatology*, *46*(5), S27-S35. https://doi.org/10.1067/mjd.2002.122653
29. Thiboutot, D., & Lookingbill, D. P. (1995). Acne: a review of new approaches to treatment and concepts of pathogenesis. *Journal of the American Academy of Dermatology*, *32*(3), S39-S46. https://doi.org/10.1016/0190-9622(95)90633-9
30. Bjerke, J. R. (2002). Azelaic acid: a treatment for rosacea. *Journal of the European Academy of Dermatology and Venereology*, *16*(5), 488-493. https://doi.org/10.1046/j.1468-3083.2002.00465.x
31. Bush, K. (2012). Antimicrobial agents. *Infectious Disease Clinics of North America*, *26*(4), 745-759. https://doi.org/10.1016/j.idc.2012.08.002
32. Fitton, A., & Goa, K. L. (1991). Azelaic acid: a review of its pharmacological properties and therapeutic efficacy in acne and hyperpigmentary skin disorders. *Drugs*, *41*(5), 780-798. https://doi.org/10.2165/00003495-199141050-00008
33. Leyden, J. J. (2001). Current issues in antimicrobial therapy for the treatment of acne. *Journal of the European Academy of Dermatology and Venereology*, *15*(3), 51-55. https://doi.org/10.1046/j.1468-3083.2001.00310.x
34. Thiboutot, D. (2008). New treatments and therapeutic strategies for acne. *Archives of Dermatology*, *144*(1), 135-140. https://doi.org/10.1001/archdermatol.2007.34
35. Grimes, P. E. (1995). The safety and efficacy of azelaic acid in ethnic skin. *Journal of the American Academy of Dermatology*, *32*(5), 758-766. https://doi.org/10.1016/0190-9622(95)90849-3
36. Thiboutot, D., & Lookingbill, D. P. (2003). Azelaic acid (AzA) 20% cream in the treatment of acne vulgaris: a multicenter, double-blind, randomized, vehicle-controlled study. *Journal of the American Academy of Dermatology*, *48*(6), 978-985. https://doi.org/10.1067/mjd.2003.274
37. Bartlett, J. G. (2002). Clinical practice. Antibiotic-associated diarrhea. *New England Journal of Medicine*, *346*(5), 334-339. https://doi.org/10.1056/NEJMcp011603
38. Chambers, H. F. (2001). The changing epidemiology of Staphylococcus aureus? *Emerging Infectious Diseases*, *7*(2), 178-182. https://doi.org/10.3201/eid0702.010204
39. Del Rosso, J. Q., & Zeichner, J. A. (2016). The clinical relevance of azelaic acid in treating acne vulgaris and rosacea: a review. *Dermatology Clinics*, *34*(2), 173-184. https://doi.org/10.1016/j.det.2015.11.004

40. Draelos, Z. D. (2006). The rationale for advancing the use of azelaic acid for the treatment of acne. *Journal of Drugs in Dermatology*, *5*(1), 6-9.

41. Norrby, S. R. (2008). Side effects of cephalosporins. *Drugs*, *25*(5), 24-29. https://doi.org/10.2165/00003495-198325050-00007

42. Paterson, D. L., & Bonomo, R. A. (2005). Extended-spectrum beta-lactamases: a clinical update. *Clinical Microbiology Reviews*, *18*(4), 657-686. https://doi.org/10.1128/CMR.18.4.657-686.2005

43. Pichichero, M. E. (2006). Cephalosporins can be prescribed safely for penicillin-allergic patie8nts. *Journal of Family Practice*, *55*(2), 106-112.